reports
Aileron Therapeutics Announces Closing of Underwritten Registered Dire...
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announ...
SIGA Technologies to Host Business Update Call on May 7 Following Rele...
SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, May 7, 2024. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at under t...
Aileron Therapeutics Announces Pricing of Underwritten Registered Dire...
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million Includes initial funding of approximately $20 million, as well as the potential for additional proceeds of approximately $20 million from exercise of three-year warrants issued in offering AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonar...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phas...
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF) Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluatin...
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financi...
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Topline results from Phase 1b study of LTI-03, a novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected to be reported in the third quarter of 2024 Cash runway expected to fund operations and key milestones into the fourth quarter of 2024 AUSTIN, Texas, April 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”, the “Company”, “we”, “our” or “us”) (NASDAQ: ALRN), a biopharmaceutical company advancing a ...
- Sean Conroy
SIGA Technologies - Positive signals abound
SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and executing its international development efforts, a key growth pillar. The amended terms allow the company to actively manage future promotion activities outside the US (effective 1 June 2024). While Meridian will continue to administer existing international contracts, we expect the renegotiated terms to benefit the bottom line in the medium term as SIGA gains...
SIGA Amends International Promotion Agreement with Meridian to Enhance...
SIGA Amends International Promotion Agreement with Meridian to Enhance International Growth Opportunities of Oral TPOXX® NEW YORK, April 01, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious disease, announced today that it entered into an amendment to its international promotion agreement with Meridian Medical Technologies, Inc. (Meridian). Effective June 1, SIGA will drive international promotion activities for oral TPOXX® while maintaining its contractual relationship with Meridian to mai...
SIGA Names Larry Miller General Counsel
SIGA Names Larry Miller General Counsel NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on health security and infectious diseases, announced the appointment of Larry Miller as general counsel, effective today. “With over twenty years of experience in the biopharmaceutical industry, Larry brings a proven track record of growing commercial businesses, successful mergers and acquisitions, and strong corporate governance, which are critical to driving SIGA’s continued success and growth strategies forward...
- Sean Conroy
SIGA Technologies - Onwards and upwards with strong FY23
SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries across both domestic and international markets. FY23 product revenues grew 50.8% to $130.7m, driven by Q423 BARDA deliveries and international orders, resulting in overall revenues increasing to $139.9m (+26.3% y-o-y). Barring packaging-related bottlenecks, which delayed some deliveries to Q124, there could have been incremental upside to meet our $172.6m revenue es...
SIGA Reports Financial Results for Three and Twelve Months Ended Decem...
SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2023 • Increased Product Sales to $131 Million in 2023 • Grew Pre-tax Operating Income to $84 Million in 2023 • Declared Today a Special Cash Dividend of $0.60 per Share • Corporate Update Conference Call Today at 4:30 PM ET NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2023. “In 2023, SIGA had approximately $131 million in product reven...
Aileron Therapeutics Announces CEO Transition
Aileron Therapeutics Announces CEO Transition Current President and Chief Operating Officer, Brian Windsor, Ph.D., appointed Chief Executive Officer Dr. Windsor to lead Aileron into a new era focused on advancing a pipeline of first-in-class medicines for orphan pulmonary and fibrosis diseases WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced tha...
SIGA Declares Special Cash Dividend of $0.60 Per Share
SIGA Declares Special Cash Dividend of $0.60 Per Share Represents a $0.15 Per Share Increase Over 2023 Special Dividend NEW YORK, March 12, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that its board of directors declared a special cash dividend of $0.60 per share on the company’s common stock. This represents an increase of $0.15 per share, or 33%, over the cash dividend paid in June 2023. The dividend is payable on April 11, 2024, to shareholders of record at the close of business on March 26, 2024. ...
SIGA Technologies to Host Business Update Call on March 12th, 2024 Fol...
SIGA Technologies to Host Business Update Call on March 12th, 2024 Following Release of Fourth Quarter and Full Year 2023 Financial Results NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, March 12th, 2024. Participating in the call will be Dr. Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available...
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potenti...
Aileron Therapeutics and Pulmonary Care Experts To Discuss the Potential Implications of LTI-03 for Idiopathic Pulmonary Fibrosis in Virtual Key Opinion Leader Event Topline results from Phase 1b study of LTI-03, Aileron’s novel Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis, expected in the second quarter of 2024 WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs ...
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, ...
Aileron Therapeutics to Host Key Opinion Leader Event on February 15, 2024 Panel discussion will highlight LTI-03, Aileron’s novel Caveolin-1-related peptide, for the treatment of idiopathic pulmonary fibrosis WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. (“Aileron”) (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, “Clinical Perspectives on Tre...
- Sean Conroy
SIGA Technologies - New captain to steer the ship
SIGA Technologies has appointed Dr Diem Nguyen as its new chief executive officer (CEO), effective 27 January 2024. She will be spearheading the company efforts to expand its commercial operations, following the retirement of incumbent CEO, Dr Phil Gomez (who had announced plans to retire in January 2023). Dr Nguyen has over 25 years of experience in the pharmaceutical industry and joins from Xalud Therapeutics, a clinical-stage biotechnology company, where she was the CEO. Prior to Xalud, she s...
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Ex...
SIGA Announces Appointment of Diem Nguyen, Ph.D., MBA, as New Chief Executive Officer NEW YORK, Jan. 22, 2024 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that Diem Nguyen, Ph.D., will join the Company as chief executive officer (CEO), effective January 27, 2024, and will also be appointed to the Company’s Board of Directors. SIGA’s current CEO, Dr. Phil Gomez, will retire from SIGA on January 26, 2024. “The appointment of Diem Nguyen as our new CEO marks a signifi...
- Sean Conroy
SIGA Technologies - International momentum building towards year-end
SIGA recapped several key developments in its Q3 update, signalling strong top-line momentum going into Q423. Most notably, the recent $18m procurement deal with the European Health Emergency Preparedness and Response Authority (HERA) has surprised to the upside, with more value to be unlocked, in our opinion. With upcoming BARDA (oral and IV TPOXX), Department of Defense (DoD) and HERA deliveries, Q423 will likely be a busy quarter for SIGA. We have increased our FY23 product revenue estimates ...
SIGA Reports Financial Results for Three and Nine Months Ended Septemb...
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2023 - In Third Quarter, SIGA Received U.S. Government Orders for Approximately $113 Million of Oral TPOXX and $25 Million of IV TPOXX® - - In October, Joint Procurement Framework Contract was signed by European Commission with Anticipated Initial Orders by Participating Countries of Approximately $18 Million for Oral TPOXX® (Tecovirimat) - - Corporate Update Conference Call Today at 4:30 PM ET - NEW YORK, Nov. 07, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage ph...
SIGA Technologies to Host Business Update Call on November 7th, 2023 F...
SIGA Technologies to Host Business Update Call on November 7th, 2023 Following Release of Third Quarter 2023 Financial Results NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, November 7th, 2023. Participating on the call will be Phil Gomez, Chief Executive Officer, Dennis Hruby, Chief Scientific Officer, Dr. Jay Varma, Chief Medical Officer and Daniel Luckshire, Chief Financial...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.